Malignant tumor of colon
|
0.030 |
Biomarker
|
disease |
BEFREE |
Colon cancer cell-derived 12(S)-HETE induces the retraction of cancer-associated fibroblast via MLC2, RHO/ROCK and Ca<sup>2+</sup> signalling.
|
28013338 |
2017 |
Malignant tumor of colon
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
As an example, IG-SVM achieved a classification accuracy of 90.32% for colon cancer, which is difficult to be accurately classified, only based on three genes including CSRP1, MYL9, and GUCA2B.
|
29246519 |
2017 |
Malignant tumor of colon
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
MBNL1-AS1 and MYL9 were poorly expressed in colon cancer.
|
31255531 |
2020 |
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Comparative transcriptomic analysis and real-time PCR analysis showed that expression of signaling molecules regulating several tumor properties including migration (MYL9), metastasis (CEACAM6, VEGFC, CX3CL1, CST1, CCL5, S100A9, IGF1, NOTCH3), adhesion (FN1, CEACAM1) and inflammation (TRAF2, NFκB2 and RelB) were altered in A549L6 cells.
|
26090868 |
2015 |
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, MYL9 was mainly expressed in the cytoplasm of stromal cells of prostate tissues, and the decreased expression of MYL9 in PCa tissues was significantly correlated with the older age of patients (P = 0.011), the higher Gleason score (P < 0.001), the advanced pathological stage (P = 0.002), the presence of metastasis (P < 0.001) and PSA failure (P = 0.001).
|
24338276 |
2014 |
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Myosin light chain 9 (MYL9) is necessary for cytoskeletal dynamics and experimental metastasis, but its expression in esophageal squamous cell carcinoma (ESCC) has not been addressed.
|
28388691 |
2017 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
And then, the expression levels of two selected genes in the down-regulated co-pathways, myosin light chain kinase (MYLK) and myosin regulatory light chain 9 (MYL9), were determined in tumor, paired paraneoplastic, and normal lung tissues.
|
25179839 |
2014 |
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Patients with high MYL9 expression in the tumor cells had poorer overall survival (OS) and recurrence-free survival.
|
28388691 |
2017 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The significance for pVHL function of two further genes upregulated by wild-type pVHL was initially unclear, but re-expression of GNG4 (G protein gamma-4 subunit/guanine nucleotide-binding protein-4) and MLC2 (myosin light chain) in a RCC cell line suppressed tumour cell growth. pVHL regulation of CDKN1C, SPARC and GNG4 was not mimicked by hypoxia, whereas for six of 11 novel targets analysed (including DOC-2/DAB2 and MLC2) the effects of pVHL inactivation and hypoxia were similar.
|
15824735 |
2005 |
Colon Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
MBNL1-AS1 and MYL9 were poorly expressed in colon cancer.
|
31255531 |
2020 |
Colon Carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
As an example, IG-SVM achieved a classification accuracy of 90.32% for colon cancer, which is difficult to be accurately classified, only based on three genes including CSRP1, MYL9, and GUCA2B.
|
29246519 |
2017 |
Colon Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Colon cancer cell-derived 12(S)-HETE induces the retraction of cancer-associated fibroblast via MLC2, RHO/ROCK and Ca<sup>2+</sup> signalling.
|
28013338 |
2017 |
Cardiomyopathy, Hypertrophic, Familial
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
This study focuses on the aspartic acid to valine substitution (D166V) in the myosin RLC shown to be associated with a malignant phenotype of familial hypertrophic cardiomyopathy (FHC).
|
24374283 |
2014 |
Cardiomyopathy, Hypertrophic, Familial
|
0.030 |
PosttranslationalModification
|
disease |
BEFREE |
Our data suggest that myosin RLC phosphorylation may have important translational implications for the treatment of RLC mutations-induced HCM and possibly play a role in other disease settings accompanied by depressed Ser15-RLC phosphorylation.
|
31101927 |
2019 |
Cardiomyopathy, Hypertrophic, Familial
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The E22K mutation of myosin RLC that causes familial hypertrophic cardiomyopathy increases calcium sensitivity of force and ATPase in transgenic mice.
|
16076902 |
2005 |
Hyperlipoproteinemia Type IIa
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
This study focuses on the aspartic acid to valine substitution (D166V) in the myosin RLC shown to be associated with a malignant phenotype of familial hypertrophic cardiomyopathy (FHC).
|
24374283 |
2014 |
Hyperlipoproteinemia Type IIa
|
0.020 |
Biomarker
|
disease |
BEFREE |
Prolonged Ca2+ and force transients in myosin RLC transgenic mouse fibers expressing malignant and benign FHC mutations.
|
16837010 |
2006 |
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Two of these, MYH9 (NMHCIIa) and MYL9 (MLC2), are also required for invasion and lung colonization.
|
19198601 |
2009 |
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
MRCK-mediated invasion occurred via downstream signaling to effector molecules MYPT1 and MLC2.
|
30279244 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These findings suggested that low MYLK and MYL9 expressions might be associated with the development of NSCLC.
|
25179839 |
2014 |
Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The significance for pVHL function of two further genes upregulated by wild-type pVHL was initially unclear, but re-expression of GNG4 (G protein gamma-4 subunit/guanine nucleotide-binding protein-4) and MLC2 (myosin light chain) in a RCC cell line suppressed tumour cell growth. pVHL regulation of CDKN1C, SPARC and GNG4 was not mimicked by hypoxia, whereas for six of 11 novel targets analysed (including DOC-2/DAB2 and MLC2) the effects of pVHL inactivation and hypoxia were similar.
|
15824735 |
2005 |
Hypertrophic Cardiomyopathy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In summary, even though R58Q expression was restricted to the heart of mice, functional similarities were clearly observed between the hearts and slow-twitch skeletal muscle, suggesting that MYL2 mutated models of hypertrophic cardiomyopathy may be useful research tools to study the molecular, structural, and energetic mechanisms of cardioskeletal myopathy associated with myosin RLC.-Kazmierczak, K., Liang, J., Yuan, C.-C., Yadav, S., Sitbon, Y. H., Walz, K., Ma, W., Irving, T. C., Cheah, J. X., Gomes, A. V., Szczesna-Cordary, D. Slow-twitch skeletal muscle defects accompany cardiac dysfunction in transgenic mice with a mutation in the myosin regulatory light chain.
|
30365366 |
2019 |
Endometriosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Three proteins, collapsin response mediator protein 2 (CRMP2), ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCH-L1) and myosin regulatory light polypeptide 9 (MYL9), were simultaneously identified from the two sets of samples from females with or without endometriosis by two-dimensional electrophoresis (2-DE).
|
23670619 |
2013 |
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, we aimed to study the expression pattern and clinical significance of MYL9 in GBM.
|
31270134 |
2019 |
Glomerulonephritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the kidney and immune organs, only Ifi202 expression increased with the development of GN in B6.MRLc1(82-100), and significant differences from C57BL/6 were observed even before disease onset.
|
20167632 |
2010 |